The aim of this study was to evaluate the plasma trough concentrations (C 0 ) of mycophenolic acid (MPA) and its major metabolite MPA 7-O-glucuronide (MPAG) in metal cation (MC)(؊) (non-treated) and MC(؉) (cotreated) patients who received tacrolimus (Tac) or cyclosporine (CyA). Fifty-nine Japanese stable kidney transplant recipients receiving immunosuppressive regimens containing mycophenolate mofetil (MMF) and a calcineurin inhibitor (CNI) were included in this study. Seven in the 25 patients receiving Tac and 8 in the 34 patients receiving CyA were treated with concomitant MCs administration. Multiple regression analysis revealed that concomitant MCs and CyA administration influenced MPA C 0 . Their standardized partial regression coefficients were ؊0.29 and ؊0.41, respectively. Stratified analysis based on CNI treatment revealed that MPA C 0 decreased significantly by 56% with concomitant MCs administration in Tac-treated patients. There was no significant difference in MPA C 0 between the MC(؊) and MC(؉) groups in CyA-treated patients. With respect to MPAG C 0 , MC(؉) group tended to be lower by 26% than MC(؊) group in Tac-treated patients. There was no significant difference in MPAG C 0 between the MC(؊) and MC(؉) groups in CyA-treated patients. Concomitant MCs administration did not affect the C 0 ratio of MPAG to MPA in either Tac-or CyA-treated patients. In conclusion, MCs co-administration decrease MPA C 0 in patients receiving Tac and may cause lower MPA exposure. There are little pharmacokinetic interactions between MMF and concomitant MCs in CyA-treated patients.
Mycophenolic acid (MPA), an active component of the prodrug mycophenolate mofetil (MMF), is an immunosuppressant, which effectively prevents rejection after kidney transplantation. 1) MPA is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) at the phenolic hydroxyl group to form the inactive metabolite MPA 7-Oglucuronide (MPAG), which mainly undergoes urinary excretion. In triple immunosuppressive regimens including MMF, calcineurin inhibitors (CNIs), and glucocorticoids, concomitant CNIs cause pharmacokinetic interactions with MPA and MPAG. [2] [3] [4] [5] [6] An example of such interactions is the inhibition of the biliary excretion of MPAG by cyclosporine (CyA). 7, 8) MMF and MPA contain 4-hydroxy radical and 3-oxo-benzofuran groups that may be involved in the formation of a chelate complex with a divalent or trivalent metal cation (MC). However, the pharmacokinetic interactions between MMF and concomitant MCs have not been fully characterized in clinical practice.
The authors experienced the opportunity to co-administer MCs with MMF in kidney transplant recipients. Iron deficiency and secondary hyperparathyroidism are often observed in stable kidney transplant recipients. 9) Kidney transplant recipients who undergo parathyroidectomy can develop hypocalcemia that requires treatment with calcium preparations. As previously reported, oral administration of ferrous sulfate decreased MMF intestinal absorption to 10% in healthy subjects. 10) There was a 50% reduction in MMF intestinal absorption when calcium polycarbophil was co-administered with MMF in healthy subjects. 11) However, recent reports have demonstrated that MPA pharmacokinetics was unchanged in kidney transplant patients treated with a combination of iron preparations and MMF. [12] [13] [14] On the other hand, antacid containing aluminum hydroxide and magnesium oxide reduced MPA and MPAG exposure in rheumatoid arthritis patients. 15) MPAG undergoes enterohepatic recirculation (EHR) and its contribution to total MPA exposure is 10-60% in humans. 16) There is clinical evidence indicating that inhibition of EHR by CyA could explain the differences observed in MPA pharmacokinetics when co-administered with either Tac or CyA. 17) The aim of this study was to evaluate the MPA C 0 and MPAG C 0 as well as the ratio of MPAG to MPA between MC(Ϫ) (non-treated) and MC(ϩ) (co-treated) patients in a stratified analysis based on CNI treatment.
MATERIALS AND METHODS

Ethics
This study was performed in accordance with the Declaration of Helsinki and its amendments, and its protocol was approved by The Ethics Committee of Hamamatsu University Hospital. Each patient received information about the scientific aim of the study and each provided written informed consent.
Patients and Study Schedule A total of 59 Japanese kidney transplant recipients receiving an immunosuppressive regimen containing CNIs and MMF (CellCept ® , Chugai Pharmaceutical, Tokyo) more than 3 months post-transplantation at Hamamatsu University Hospital was included in the study (Table 1) . Seven in the 25 patients receiving Tac (Prograf ® , Astellas Pharma, Tokyo) and 8 in the 34 patients re-ceiving CyA (Neoral ® , Novartis Pharma, Tokyo) were concomitantly treated with MC preparations ( Table 2) . Exclusion criteria of the enrollment were: (1) patients on hemodialysis or peritoneal dialysis; (2) patients with serum creatinine concentration exceeding 3 mg/dl; (3) patients with poor adherence on medication. All enrolled patients had been receiving fixed dosages of immunosuppressants for at least two weeks before testing. Plasma concentrations of MPA and MPAG had not been monitored until participation in the present study. Blood specimens were drawn into tubes containing EDTA at 12 h after oral administration of MMF and before morning dosing.
Simultaneous Determination of MPA and MPAG in Plasma MPA was purchased from Sigma (St. Louis, MO, U.S.A.). MPAG was purchased from Analytical Services International (London, U.K.). All other reagents were analytical grade and commercially available. After quantification of Tac by monoclonal microparticle enzyme immunoassay or CyA by affinity column mediated immunoassay, plasma specimen was stored at Ϫ35°C. Simultaneous determination of plasma MPA and MPAG concentrations was performed by ion-pair HPLC as previously described. 18) The plasma extracts were separated with acetonitrile and 30 mM tetran-butylammonium bromide containing 5 mM ammonium acetate at pH 9.0 (33/67, v/v) at a flow rate of 1 ml/min. Chromatographic separation of each analyte was performed with an ODS column (TSK-GEL ® ODS-80Ts, 5 mm, 150ϫ4.6 mm i.d., Tosoh, Tokyo) maintained at 40°C. The wavelength of the UV detector was set at 250 nm. Lower limit of quantifications for MPA and MPAG in plasma were 50 and 100 ng/ml, respectively. Small intra-and interassay coefficients of variation were obtained with respect to the accuracy and reproducibility for determination of MPA and MPAG (Ͻ6.5%).
Statistical Analysis All statistical analyses were performed using SPSS (11.5J, SPSS Japan Inc., Tokyo). Multiple regression analysis was performed to examine as to whether CyA and MCs administration influenced MPA C 0 . MPA C 0 , MPAG C 0 , and the ratio of MPAG to MPA was compared in each group in stratified analysis based on CNI and MCs treatment using a one-way analysis of variance and post-hoc Bonferroni test. In MC(Ϫ) patients, correlation of non-dose-normalized CNI C 0 with the C 0 ratio of MPAG to MPA was evaluated in simple regression analysis. All values were presented as meanϮS.D. unless otherwise stated. A pϽ0.05 was considered to indicate statistical significance. Table 3 shows the results of multiple regression analysis applied to investigate the influence of concomitant MCs and CyA administration in MPA C 0 in 59 kidney transplant recipients. MPA C 0 was significantly determined by two possible factors as following order; CyA (standardized partial regression coefficient [b]ϭϪ0.41, pϽ0.01) and MC (bϭϪ0.29, pϭ0.02). There was no multicollinearity between two indicators (variance inflation factor Ͻ10). Figure 1A shows the influence of concomitant MCs administration on MPA C 0 in stratified analysis based on CNI treatment. MPA C 0 decreased significantly by 56% with concomitant MCs administration in Tac-treated patients (0.28Ϯ 0.06 mg/ml per mg/kg to 0.12Ϯ0.04 mg/ml per mg/kg, pϽ0.01). There was no significant difference in MPA C 0 between the MC(Ϫ) and MC(ϩ) groups in CyA-treated patients; the values were 0.16Ϯ0.06 mg/ml per mg/kg versus 0.19Ϯ0.04 mg/ml per mg/kg. In the MC(Ϫ) patients, MPA C 0 was significantly higher in Tac-treated than that in CyAtreated group (pϽ0.01). MPA C 0 tended to be lower in Tactreated MC(ϩ) than that in CyA-treated MC(ϩ) group (pϭ0.11). Figure 1B shows the influence of concomitant MCs administration on MPAG C 0 in stratified analysis based on CNI treatment. MPAG C 0 tended to decrease by 26% with concomitant MCs administration in Tac-treated patients (4.2Ϯ2.1 mg/ml per mg/kg to 3.1Ϯ2.4 mg/ml per mg/kg). There was no significant difference in MPAG C 0 between the MC(Ϫ) and MC(ϩ) groups in CyA-treated patients; the values were 7.1Ϯ3.7 mg/ml per mg/kg versus 7.9Ϯ3.0 mg/ml per mg/kg. In either MC(Ϫ) or MC(ϩ) patients, MPAG C 0 was significantly higher in CyA-treated than in Tac-treated group (pϭ0.02, respectively).
RESULTS
Influence of Concomitant MCs and CyA Administration on MPA C 0 in Multiple Regression Analysis
Influence of Concomitant MCs Administration on MPA C 0 in Stratified Analysis Based on CNI Treatment
Influence of Concomitant MCs Administration on MPAG C 0 in Stratified Analysis Based on CNI Treatment
Influence of CNI C 0 and Concomitant MCs Administration on the C 0 Ratio of MPAG to MPA on Each CNI Treatment
There was no significant correlation between Tac C 0 and the C 0 ratio of MPAG to MPA in Tac-treated MC(Ϫ) patients (pϭ0.35, rϭϪ0.24). In contrast, CyA C 0 significantly correlated with the C 0 ratio of MPAG to MPA in CyA-treated MC(Ϫ) patients (pϭ0.02, rϭ0.45). Figure 1C shows the influence of concomitant MCs administration on the C 0 ratio of MPAG to MPA in each CNI treatment. The C 0 ratio of MPAG to MPA did not differ significantly between the MC(Ϫ) and MC(ϩ) groups in either Tac-treated patients (9.5Ϯ3.9 versus 15.3Ϯ7.5) or CyA-treated patients (29.6Ϯ 13.0 versus 26.5Ϯ9.8). In the MC(Ϫ) patients, the C 0 ratio of MPAG to MPA was significantly higher in CyA-treated than in Tac-treated group (pϽ0.01). The C 0 ratio of MPAG to MPA also tended to be higher by 73% in CyA-treated MC(ϩ) group than that in Tac-treated MC(ϩ) group (pϭ0.22).
DISCUSSION
Drug interactions between MMF and concomitantly administered CNIs, glucocorticoids, or MCs can explain the large interindividual variation in MPA pharmacokinetics. In immunosuppressive regimens that consist of MMF and CNI, concomitant CyA inhibits the biliary excretion of MPAG, 7, 8) suggesting the contribution of EHR to MPA exposure is different between CNI treatments. 17) With respect to interactions between MMF and glucocorticoids, Cattaneo et al. 1294 Vol. 31, No. 6 reported that concomitant glucocorticoids interfered with MMF bioavailability during the early period following kidney transplantation. 6) Our previous reports demonstrated that CNI rather than glucocorticoid treatment influenced pharmacokinetic interindividual variation during the maintenance period. 19) On the other hand, the pharmacokinetic interactions between MMF and concomitant MCs have not been fully characterized in clinical practice. [12] [13] [14] [15] Multiple regression analysis revealed that concomitant MCs and CyA administration influenced significantly MPA pharmacokinetics in this study. Although the b value of MCs was lower than that of CyA, concomitant MCs administration caused significant interindividual variation of MPA C 0 (Table  3 ). In addition, there was no multicollinearity between MCs and CyA, and those factors independently influenced MPA C 0 . In stratified analysis, this study found a significant reduction in MPA C 0 with concomitant MCs administration in patients treated with Tac. These results indicate that MCs coadministration may cause the pharmacokinetic interactions in patients receiving combination therapy with Tac. Morii et al. demonstrated a 90% reduction of MMF bioavailability in healthy subjects concomitantly treated with iron. 10) They hypothesized that MCs form chelate complexes with the 4-hydroxy radical and 3-oxo-benzofuran groups of MMF, with the result that iron might restrict intestinal absorption of MMF. Kato et al. also reported a 50% reduction in MMF intestinal absorption when it was co-administered with calcium polycarbophil. 11) Moreover, antacid containing aluminum hydroxide and magnesium oxide have been shown to reduce MMF bioavailability in rheumatoid arthritis patients. 15) These reports indicate that MCs co-administration affects MMF bioavailability in subjects receiving immunosuppression without CNI treatment. Taking those reports above into consideration, our findings suggested that the kind of CNI influenced the pharmacokinetic interactions between MMF and MCs.
In contrast with the above reports, some groups have demonstrated that oral iron therapy does not affect MPA pharmacokinetics during the early and maintenance periods following kidney transplantation. [12] [13] [14] They concluded that the practice of routinely giving oral iron to such patients is safe from a drug interaction standpoint. Although the contribution of EHR with respect to MPAG is different between CNI treatments, they evaluated the pharmacokinetic interactions between MMF and MCs without classifying the patients into Tac-or CyA-treated groups. Therefore, stratified analysis based on CNI treatment is needed in order to evaluate the pharmacokinetic interactions with MCs. For chelate formation between MPA and MCs, the presence of iron ion affects the size of the chelate complex and its permeability through cellulose membranes, 11) but not the physicochemical properties of MPA. 20, 21) The reason for the differences observed in healthy subjects between the recent report of Ducray et al. 22) and that of Morii et al. 10) was not clarified by the findings of the present study. Our study is the first report on effect of MCs co-administration on MPA pharmacokinetics in stratified analysis based on CNI treatment.
MCs co-administration decreased MPA C 0 and tended to decline MPAG C 0 (26%) in Tac-but not CyA-treated patients. CyA interferes with the EHR of MPAG, possibly via the multidrug resistance-associated protein 2. 7,23) MPAG un-dergoes EHR and its contribution to total MPA exposure is 10-60%. 16) Pharmacokinetic modeling that includes EHR can explain the differences observed in MPA pharmacokinetics between the CNI treatments. 17) In contrast, Tac was reported to suppress MPA glucuronidation via inhibition of UGT in vitro. 5) However, the inhibitory effect of MPA glucuronidation by Tac on pharmacokinetics of MPA has not been reported in kidney transplant recipients. This study evaluated the relationship between Tac C 0 with the C 0 ratio of MPAG to MPA, and the correlation was not found between them. Therefore, we confirmed that the effect of Tac on MPA C 0 could be disregarded in kidney transplant recipients. Taking factors above into consideration, this study hypothesize that there is a certain contribution of an interaction between MCs and MPA derived from biliary-excreted MPAG in the intestinal tract to MPA pharmacokinetics, and the interaction depends on the amount of biliary-excreted MPAG. Actually, there was little pharmacokinetic interaction of MCs in the CyA-treated patients in this study. In addition, MCs co-administration did not affect the C 0 ratio of MPAG to MPA in stratified analysis based on the CNI treatment. This finding suggests that MCs co-administration does not affect the hepatic glucuronidation of MPA or biliary excretion of MPAG in stable kidney transplant recipients. This study regarded that effect of MCs on MPA C 0 in Tac-treated patients may be caused by formation of a chelate complex with MPA rather than inhibition of hepatic glucuronidation of MPA and biliary excretion of MPAG. In contrast, hepatic glucuronidation of MPA and biliary excretion of MPAG determined the C 0 ratio of MPAG to MPA.
There is increasing evidence that therapeutic drug monitoring of MPA helps to diminish adverse drug reactions and long-term over immunosuppression. [24] [25] [26] Although MPA C 0 is generally known as a poor marker for the concentration-time curve (AUC), C 0 sufficiently reflects interindividual variation of MPA pharmacokinetics based on drug interactions in kidney transplant recipients. 2, 3) In addition, weak correlations have been reported between C 0 and AUC of MPA, most likely due to time-dependent change in renal function and concomitant CNIs. 27) Large intraindividual variation in MPA C 0 was also associated with poor renal function and proteinuria. 28) In this study, the enrolled kidney transplant recipients had stable renal function (serum creatinine concentration not exceeding 3 mg/dl) and had been receiving an unchanged immunosuppressant regimen for at least two months. We believe that consideration of the contribution of EHR to total MPA exposure and stratified analysis based on the CNI treatment were needed for evaluation of the pharmacokinetic interaction between MMF and concomitant MCs.
This study evaluated the influence of concomitant MCs administration on the pharmacokinetics of MPA and MPAG without distinguishing the kind of MC. Kato et al. reported that the stability of the chelate complexes was different between iron ion and calcium ion. 11) There may be also differences in the degree of interactions among various kinds of MC. In clinical practice, medicines that form chelate complex with MCs need to avoid a combination regardless of the kind of MC. Although further clinical studies need to be conducted in order to elucidate the pharmacokinetic interactions between MMF and individual MCs in stratified analysis based on the CNI treatment, this clinical study revealed pre-liminarily the drug interaction between MMF and concomitant MCs.
The authors observed that co-administered MCs decreased MPA C 0 and could increase MPA clearance in Tac-but not CyA-treated stable kidney transplant patients. CyA has been reported to inhibit the biliary excretion of MPAG, suggesting the contribution of EHR in MPA pharmacokinetics is different between CNI treatments. Our findings suggested that the drug interactions between MMF and MCs might depend on the amount of biliary-excreted MPAG-derived MPA in the gastrointestinal tract. In conclusion, MCs co-administration decrease MPA C 0 in patients receiving Tac and may cause lower MPA exposure. There are little pharmacokinetic interactions between MMF and concomitant MCs in CyA-treated patients.
